Ubr1 Activators
UBR1 Activators, primarily through indirect mechanisms, modulate the activity of UBR1, an E3 ubiquitin ligase involved in the N-end rule pathway of protein degradation. Proteasome inhibitors like MG-132 [Z-Leu- Leu-Leu-CHO], Lactacystin, Epoxomicin, and Bortezomib play a significant role in this modulation. By inhibiting proteasomal degradation, these compounds lead to the accumulation of proteins within the cell. This increase in the pool of proteins, particularly those tagged for degradation, potentially enhances the substrates available for UBR1-mediated ubiquitination. As a result, UBR1 activity is indirectly stimulated, as it targets these accumulated proteins for degradation, thereby maintaining protein quality control within the cell.
In addition to proteasome inhibitors, inhibitors of other proteolytic pathways like Leupeptin, Hemisulfate, E-64, ALLN (peptide), Pepstatin A, and Chloroquine also contribute to the modulation of UBR1 activity. These compounds, by inhibiting lysosomal proteases, calpains, and other proteases, alter the cellular protein degradation landscape. This alteration leads to an increased availability of substrates for UBR1, indirectly enhancing its ubiquitin ligase activity. Collectively, these indirect activators and conditions underscore the integral role of UBR1 in maintaining protein homeostasis under various cellular states, highlighting its importance in the ubiquitin-proteasome system.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132 [Z-Leu- Leu-Leu-CHO] is a proteasome inhibitor that can indirectly increase UBR1 activity. By inhibiting proteasomal degradation, MG-132 [Z-Leu- Leu-Leu-CHO] leads to the accumulation of proteins, potentially increasing substrates for UBR1-mediated ubiquitination. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Lactacystin, another proteasome inhibitor, indirectly affects UBR1 activity. It causes an accumulation of ubiquitinated proteins, which may enhance UBR1's role in targeting proteins for degradation. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
Epoxomicin is a selective proteasome inhibitor. Its inhibition of the proteasome can lead to increased levels of proteins that become substrates for UBR1, indirectly enhancing its ubiquitination activity. | ||||||
Leupeptin hemisulfate | 103476-89-7 | sc-295358 sc-295358A sc-295358D sc-295358E sc-295358B sc-295358C | 5 mg 25 mg 50 mg 100 mg 500 mg 10 mg | $73.00 $148.00 $316.00 $499.00 $1427.00 $101.00 | 19 | |
Leupeptin, Hemisulfate, an inhibitor of lysosomal proteases, can indirectly affect UBR1 by altering protein degradation pathways, potentially increasing the substrates available for UBR1-mediated ubiquitination. | ||||||
E-64 | 66701-25-5 | sc-201276 sc-201276A sc-201276B | 5 mg 25 mg 250 mg | $281.00 $947.00 $1574.00 | 14 | |
E-64, a cysteine protease inhibitor, may indirectly enhance UBR1 activity by altering the cellular protein degradation landscape, leading to an increased availability of substrates for UBR1. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine, by inhibiting lysosomal function, can indirectly increase substrates for UBR1-mediated ubiquitination, as it affects protein degradation pathways. | ||||||
Autophagy Inhibitor, 3-MA | 5142-23-4 | sc-205596 sc-205596A | 50 mg 500 mg | $65.00 $261.00 | 113 | |
3-Methyladenine, an autophagy inhibitor, may indirectly enhance UBR1 activity by affecting protein turnover and increasing the availability of substrates for ubiquitination. | ||||||